SLCO1B3 and prostate carcinoma: Tumoral OATP1B3 expression is related to the clinical response of patients with prostate cancer treated with abiraterone and has been shown to determine intracellular concentrations of docetaxel and cabazitaxel in patient-derived xenografts11,12.